Nevertheless, although CDKN2A homozygous deletion was rare in our cohort, with only one case of PA, its presence in cases of low-grade MAPK-induced gliomas showed a dramatic clinical evolution, pointing out the possibly strong prognostic impact of CDKN2A homozygous deletion in those populations [23,24]. Here, CDKN2A is linked to central nervous system cancer.